Sugi Predict

Sugi Predict / Compounds / SCHEMBL2447401

SCHEMBL2447401

SCHEMBL2447401

NC(=O)C1CN(Cc2ccccc2)CCO1

nearest known ligand 0.56

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ DRD4 P21917 10/20 0.56
▸ DRD2 P14416 2/20 0.52
▸ DRD3 P35462 2/20 0.52
▸ GRIN2B Q13224 2/20 0.50
▸ SIRT1 Q96EB6 1/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ CYP2D6 P10635 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ GRN P28799 1/20 0.47
▸ SORT1 Q99523 1/20 0.47
▸ CNR2 P34972 2/20 0.47
▸ ALDH1A1 P00352 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12696566 1.00 DRD4 (0.56) DRD4DRD2DRD3GRIN2BSIRT1
SCHEMBL3519935 0.90 DRD4 (0.57) DRD4DRD2DRD3GRIN2BCYP1A2
SCHEMBL27641050 0.90 DRD4 (0.57) DRD4DRD2DRD3GRIN2BCYP1A2
SCHEMBL159384 0.90 DRD4 (0.57) DRD4DRD2DRD3GRIN2BCYP1A2
SCHEMBL3521678 0.90 DRD4 (0.57) DRD4DRD2DRD3GRIN2BCYP1A2
SCHEMBL4129378 0.88 DRD4 (0.56) DRD4DRD2DRD3GRIN2BCYP1A2
SCHEMBL4836218 0.88 DRD4 (0.56) DRD4DRD2DRD3GRIN2BCYP1A2
Hydrochloric Acid SCHEMBL12610644 0.88 DRD4 (0.56) DRD4DRD2DRD3GRIN2BCYP1A2
Hydrochloric Acid SCHEMBL12610726 0.88 DRD4 (0.56) DRD4DRD2DRD3GRIN2BCYP1A2
Hydrochloric Acid SCHEMBL917642 0.88 DRD4 (0.56) DRD4DRD2DRD3GRIN2BCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11746091-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2023-09-05 — — US disclosed
US-20230033510-A1 Compounds and Methods for Treatment of Visceral Pain ARENA PHARMACEUTICALS, INC. 2023-02-02 — — US disclosed
US-11214548-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2022-01-04 — — US disclosed
US-20210188781-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2021-06-24 — — US disclosed
EP-3621619-A1 COMPOUNDS AND METHODS FOR TREATMENT OF VISCERAL PAIN Arena Pharmaceuticals, Inc. (US) 2020-03-18 — — EP disclosed
US-20200078358-A1 Compounds and Methods for Treatment of Visceral Pain ARENA PHARMACEUTICALS, INC. 2020-03-12 — — US disclosed
CN-110709085-A Compounds and methods for treating visceral pain 艾尼纳制药公司 2020-01-17 — — CN disclosed
US-20180354907-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2018-12-13 — — US disclosed
WO-2018208847-A1 COMPOUNDS AND METHODS FOR TREATMENT OF PAIN FROM INFLAMMATORY BOWEL DISEASE ARENA PHARMACEUTICALS, INC. (US) 2018-11-15 — — WO disclosed
WO-2018208848-A1 COMPOUNDS AND METHODS FOR TREATMENT OF VISCERAL PAIN ARENA PHARMACEUTICALS, INC. (US) 2018-11-15 — — WO disclosed
EP-3363788-A1 CANNABINOID RECEPTOR MODULATORS Arena Pharmaceuticals, Inc. (US) 2018-08-22 — — EP disclosed
US-9944606-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2018-04-17 — — US disclosed
CN-102596913-B Cannabinoid receptor modulators 艾尼纳制药公司 2016-11-09 — — CN disclosed
US-20150073177-A1 METHOD FOR INHIBITING TRYPANOSOMA CRUZI HOWARD UNIVERRSITY (US) 2015-03-12 — — US disclosed
US-8778950-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2014-07-15 — — US disclosed
US-20130165412-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2013-06-27 — — US disclosed
US-20120214766-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2012-08-23 — — US disclosed
EP-2470508-A1 CANNABINOID RECEPTOR MODULATORS Arena Pharmaceuticals, Inc. (US) 2012-07-04 — — EP disclosed
EP-2362775-A1 CHEMICAL COMPOUNDS GlaxoSmithKline LLC (US) 2011-09-07 — — EP disclosed
WO-2010059658-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-05-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214766-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 DRD4 2045/4885DRD2 1476/4885DRD3 1764/4885
US-20200078358-A1 Compounds and Methods for Treatment of Visceral Pain VIP, FABP2, FABP6 DRD4 3676/4885DRD2 2344/4885DRD3 2159/4885
US-20180354907-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 DRD4 2045/4885DRD2 1476/4885DRD3 1764/4885
US-20150073177-A1 METHOD FOR INHIBITING TRYPANOSOMA CRUZI PCNA, NQO1, NQO2 DRD4 4272/4885DRD2 4557/4885DRD3 4123/4885
US-11746091-B2 Cannabinoid receptor modulators CNR1, CNR2, TRPV1 DRD4 2045/4885DRD2 1476/4885DRD3 1764/4885
US-11214548-B2 Cannabinoid receptor modulators CNR1, CNR2, TRPV1 DRD4 2045/4885DRD2 1476/4885DRD3 1764/4885
US-20230033510-A1 Compounds and Methods for Treatment of Visceral Pain VIP, FABP2, FABP6 DRD4 3676/4885DRD2 2344/4885DRD3 2159/4885
US-20210188781-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 DRD4 2045/4885DRD2 1476/4885DRD3 1764/4885
US-20130165412-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 DRD4 2045/4885DRD2 1476/4885DRD3 1764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.